Indication

Indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

Medicine details

Medicine name:
delta-9-tetrahydrocannabinol and cannabidiol (Sativex)
SMC ID:
SMC2473
Pharmaceutical company
GW Pharmaceuticals Ltd
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
12 September 2022
SMC meeting date:
02 August 2022
Patient group submission deadline:
04 July 2022